Search

Strontium ranelate

It is therefore promoted as a "dual action bone agent" (DABA) indicated for use in treatment of severe osteoporosis. … Available for prescription use for a time in some parts of the world as Protelos (strontium ranelate) 2 g granules for oral suspension by Servier, it was ultimately discontinued in 2016-2017 owing to an

Pimecrolimus

It is currently available as a topic cream used in the treatment of atopic dermatitis (eczema). … Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.

Benralizumab

[A31294] It inhibits the binding of IL-5 as well as the hetero-oligomerization of the alpha and beta subunits of the IL-5R, thus blocking signal transduction. … It is an afucosylated IgG which gives it high affinity for the FcγRIIIα receptor in natural killer cells, macrophages and neutrophils.

Krypton Kr 81m

Aripiprazole lauroxil

It is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose.

Perboric acid

Perboric acid is mainly found in its salt form of sodium perborate and it can be found as a monohydrate or tetrahydrate. … [A33037] It is one of the peroxy acid salts with very wide functionalities in industrial settings.

Oritavancin

It was developed by The Medicines Company (acquired by Novartis). … It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.

Encainide

Encainide hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack.

Icosapent

It serves as the precursor for the prostaglandin-3 and thromboxane-3 families.

Glucarpidase

It prevents methotrexate toxicity in patients with renal dysfunction who are undergoing high-dose methotrexate treatment, as it provides an alternative non-renal pathway for methotrexate elimination. … [L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE.